Total Payments
$922.02
2024 Payments
$32.49
Companies
10
Transactions
39
Medicare Patients
18,095
Medicare Billing
$1.7M
Payment Breakdown by Category
Food & Beverage$922.02 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $922.02 | 39 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| LEO Pharma Inc. | $239.03 | 14 | $0 (2023) |
| Celgene Corporation | $125.00 | 1 | $0 (2017) |
| Incyte Corporation | $124.00 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $96.26 | 5 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $91.12 | 5 | $0 (2020) |
| PFIZER INC. | $89.28 | 5 | $0 (2022) |
| AbbVie Inc. | $77.70 | 4 | $0 (2021) |
| GENZYME CORPORATION | $32.49 | 1 | $0 (2024) |
| Janssen Biotech, Inc. | $27.31 | 2 | $0 (2021) |
| Sun Pharmaceutical Industries Inc. | $19.83 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.49 | 1 | GENZYME CORPORATION ($32.49) |
| 2023 | $58.60 | 3 | LEO Pharma Inc. ($58.60) |
| 2022 | $155.92 | 3 | Incyte Corporation ($124.00) |
| 2021 | $165.59 | 10 | LEO Pharma Inc. ($67.66) |
| 2020 | $95.45 | 5 | LEO Pharma Inc. ($30.51) |
| 2019 | $202.84 | 11 | LEO Pharma Inc. ($68.93) |
| 2018 | $51.54 | 3 | AbbVie, Inc. ($19.79) |
| 2017 | $159.59 | 3 | Celgene Corporation ($125.00) |
All Payment Transactions
39 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/16/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.49 | General |
| Category: Immunology | ||||||
| 12/07/2023 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: DERMATOLOGY | ||||||
| 08/10/2023 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: DERMATOLOGY | ||||||
| 01/31/2023 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: DERMATOLOGY | ||||||
| 05/03/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $124.00 | General |
| Category: Dermatology | ||||||
| 04/12/2022 | PFIZER INC. | EUCRISA (Drug), CIBINQO | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: DERMATOLOGY | ||||||
| 01/14/2022 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $13.33 | General |
| Category: DERMATOLOGY | ||||||
| 11/30/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: DERMATOLOGY | ||||||
| 09/22/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: DERMATOLOGY | ||||||
| 07/07/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: DERMATOLOGY | ||||||
| 06/15/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: DERMATOLOGY | ||||||
| 05/18/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: DERMATOLOGY | ||||||
| 05/12/2021 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Immunology | ||||||
| 04/09/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $17.92 | General |
| Category: DERMATOLOGY | ||||||
| 03/25/2021 | Janssen Biotech, Inc. | REMICADE (Biological), STELARA, SIMPONI ARIA | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: Immunology | ||||||
| 02/11/2021 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $17.54 | General |
| Category: IMMUNOLOGY | ||||||
| 01/13/2021 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: DERMATOLOGY | ||||||
| 08/10/2020 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: DERMATOLOGY | ||||||
| 08/06/2020 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.32 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/08/2020 | LEO Pharma Inc. | ENSTILAR (Drug) | Food and Beverage | In-kind items and services | $12.17 | General |
| Category: DERMATOLOGY | ||||||
| 01/29/2020 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $19.68 | General |
| 01/10/2020 | AbbVie Inc. | SKYRIZI (Biological), HUMIRA | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: IMMUNOLOGY | ||||||
| 12/18/2019 | AbbVie, Inc. | Humira (Biological), Skyrizi | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Immunology | ||||||
| 12/11/2019 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $19.83 | General |
| Category: Dermatology | ||||||
| 11/26/2019 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 19 | 4,730 | 10,629 | $846,968 | $446,391 |
| 2022 | 19 | 4,347 | 8,839 | $737,615 | $401,471 |
| 2021 | 20 | 4,643 | 9,386 | $793,820 | $452,335 |
| 2020 | 19 | 4,375 | 7,947 | $699,758 | $365,252 |
Total Patients
18,095
Total Services
36,801
Medicare Billing
$1.7M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 1,055 | 1,979 | $199,973 | $132,482 | 66.2% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 863 | 1,386 | $188,496 | $100,047 | 53.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 593 | 1,288 | $94,024 | $52,498 | 55.8% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 751 | 1,305 | $130,500 | $45,040 | 34.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 260 | 329 | $49,679 | $28,004 | 56.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 562 | 3,594 | $53,910 | $18,953 | 35.2% |
| 17263 | Destruction of cancer skin growth of trunk, arms, or legs, 2.1-3.0 cm | Office | 2023 | 96 | 109 | $29,212 | $16,158 | 55.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 65 | 88 | $21,560 | $11,961 | 55.5% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2023 | 74 | 83 | $20,335 | $10,537 | 51.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 128 | 145 | $8,845 | $6,198 | 70.1% |
| 10060 | Simple or single drainage of skin abscess | Office | 2023 | 54 | 59 | $9,676 | $5,890 | 60.9% |
| 69100 | Biopsy of ear | Office | 2023 | 89 | 104 | $14,560 | $4,759 | 32.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 56 | 56 | $8,288 | $4,629 | 55.9% |
| 11402 | Removal of noncancer skin growth of body, arms, or legs, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $4,230 | $2,258 | 53.4% |
| 17272 | Destruction of cancer skin growth of scalp, neck, hands, feet, or genitals, 1.1-2.0 cm | Office | 2023 | 17 | 18 | $4,716 | $2,165 | 45.9% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 16 | 17 | $2,907 | $1,682 | 57.9% |
| 17282 | Destruction of cancer skin growth of face, ears, eyelids, nose, lips, or mouth, 1.1-2.0 cm | Office | 2023 | 11 | 11 | $3,157 | $1,604 | 50.8% |
| 17111 | Destruction of skin growth, 15 or more growths | Office | 2023 | 12 | 15 | $2,700 | $1,505 | 55.8% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 11 | 25 | $200.00 | $21.31 | 10.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 1,058 | 1,946 | $196,640 | $129,808 | 66.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 826 | 1,284 | $174,624 | $97,333 | 55.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 672 | 1,132 | $113,200 | $40,449 | 35.7% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 509 | 915 | $66,795 | $38,960 | 58.3% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 216 | 284 | $42,884 | $24,623 | 57.4% |
| 17262 | Destruction of cancer skin growth of trunk, arms, or legs, 1.1-2.0 cm | Office | 2022 | 97 | 107 | $26,215 | $14,496 | 55.3% |
About Dr. Peggy Hunter, MD
Dr. Peggy Hunter, MD is a Dermatology healthcare provider based in Lake Worth, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1962477463.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peggy Hunter, MD has received a total of $922.02 in payments from pharmaceutical and medical device companies, with $32.49 received in 2024. These payments were reported across 39 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($922.02).
As a Medicare-enrolled provider, Hunter has provided services to 18,095 Medicare beneficiaries, totaling 36,801 services with total Medicare billing of $1.7M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location Lake Worth, FL
- Active Since 02/20/2006
- Last Updated 11/27/2023
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1962477463
Products in Payments
- ENSTILAR (Drug) $151.05
- Otezla (Drug) $125.00
- OPZELURA (Drug) $124.00
- DUPIXENT (Biological) $109.47
- EUCRISA (Drug) $89.28
- COSENTYX (Biological) $76.58
- ADBRY (Biological) $71.93
- Humira (Biological) $42.22
- SKYRIZI (Biological) $35.48
- ILUMYA (Biological) $19.83
- PICATO (Drug) $16.05
- REMICADE (Biological) $15.92
- DUPIXENT DUPILUMAB INJECTION (Biological) $14.14
- STELARA (Biological) $11.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Lake Worth
Marianne Carroll, Do, DO
Dermatology — Payments: $8,153
Dermatology $8,153
Dr. Robin Shecter, Do, DO
Dermatology — Payments: $5,332
Dermatology $5,332
Ms. Andrea Chen, M.d, M.D
Dermatology — Payments: $2,195
Dermatology $2,195
Dr. Arthur Smith, Md, MD
Dermatology — Payments: $470.26
Dermatology $470.26
Michael Sherling, M.d, M.D
Dermatology — Payments: $74.74
Dermatology $74.74